Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 2/20 | 0.48 |
| ▸ | CCKAR | P32238 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28388492 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCKBRCCKARCTSL | |
| SCHEMBL23863929 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCKBRCCKARCTSL | |
| SCHEMBL16706528 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCKBRCCKARCTSL | |
| SCHEMBL16703980 | 0.90 | DPP3 (0.49) | CCKARDPP3 | |
| SCHEMBL18103316 | 0.87 | F2 (0.47) | — | |
| SCHEMBL28392404 | 0.87 | F2 (0.47) | — | |
| SCHEMBL28394567 | 0.87 | F2 (0.56) | — | |
| SCHEMBL16706511 | 0.87 | F2 (0.56) | — | |
| SCHEMBL24447150 | 0.87 | F2 (0.56) | — | |
| SCHEMBL28388489 | 0.85 | CMA1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516023-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2026-01-06 | — | — | US | disclosed |
| CN-111187202-B | NMDA antagonist prodrugs | 阿斯利康(瑞典)有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4001272-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2024-11-13 | — | — | EP | disclosed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |